EW
Edwards Lifesciences CorpPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- May 1 to May 27 ▲ 3 buys: Ro Khanna bought $1,001 - $15,000, last disclosed Jun 11
- May 12 to May 29 ▼ 6 days of insider sells: $6.5M by 5 insiders, avg $81.50
- Jul 27 to Jul 30 ▼ 3 days of insider sells: $1.1M by 2 insiders, avg $84.81
- Aug 10 Edwards Lifesciences, et al v. Thompson, et al
- Aug 26 to Aug 31 ▼ 3 days of insider sells: $3.3M by 4 insiders, avg $90.96
- Sep 11 ▼ 1 insider sell $54.2K at $87.51
- Sep 30 ▲ 5 funds open new positions (13F)
- Oct 8 ▼ 1 insider sell $53.0K at $85.65
- Nov 4 ▲ Edwards Lifesciences reported Q3 2026 adjusted EPS of $0.80, beating…
- Nov 4 ▲ Truist Securities upgrades
- Nov 4 ▲ Earnings: EW Q3 2026 Earnings: EPS $0.8 (+5.4% vs est)
- Nov 9 to Nov 10 ▼ 2 days of insider sells: $7.5M by 3 insiders, avg $103.05
Signal stack
Where each data set points today.
- InsidersBEARISH
7 insiders sold $18.7M.
- InstitutionsBULLISH
Q3 2026: 54 added (5 new), 25 trimmed or exited. Largest new: Hrt Financial $19.6M, Lansforsakringar Fondforvaltning Ab (Publ) $16.2M.
- AnalystsBULLISH
32 of 39 rate it Buy or better. Median target $115.00 (+7%).
- Short sellersSTEADY
Short interest +0.5% to 9.38M shares. 2.8 days to cover, ≈1.6% of shares.
- TrendUPTREND
18% above its 50-day average. New closing high $107.15 on Nov 13.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | ADD | $879.9M |
| FMR LLC | TRIM | $526.5M |
| Invesco Ltd. | ADD | $443.4M |
| Assenagon Asset Management S.A. | ADD | $234.7M |
| BAILLIE GIFFORD & CO | ADD | $150.2M |
| Zurcher Kantonalbank (Zurich Cantonalbank) | DOUBLED | $122.8M |
| Qube Research & Technologies Ltd | DOUBLED | $115.0M |
| FRANKLIN TEMPLETON INC | TRIM | $69.2M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
39 analystsPrice is inside the target range. Median implies +7%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 16, 2026 | 🔒 Fresh data, subscribers only MAINTAIN | |
| Nov 11, 2026 | TD Cowen MAINTAIN | Buy |
| Nov 5, 2026 | UBS MAINTAIN | Buy |
| Nov 5, 2026 | JP Morgan MAINTAIN | Overweight |
| Nov 5, 2026 | Citigroup MAINTAIN | Buy |
| Nov 5, 2026 | Leerink Partners MAINTAIN | Outperform |
Washington
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Dahl Andrew M. SVP, Corporate Controller Nov 13, 2026 | TAX W/H | $10.7K |
Lippis Daniel J. CVP, TAVR Nov 10, 2026 | SELL | $64.5K |
Lippis Daniel J. CVP, TAVR Nov 10, 2026 | EXERCISE | $45.0K |
Zovighian Bernard J CEO Nov 9, 2026 | EXERCISE | $1.7M |
Zovighian Bernard J CEO Nov 9, 2026 | SELL | $949.5K |
Zovighian Bernard J CEO Nov 9, 2026 | SELL | $1.4M |
BOBO DONALD E JR CVP,Strategy/Corp Development Nov 9, 2026 | SELL | $5.0M |
BOBO DONALD E JR CVP,Strategy/Corp Development Nov 9, 2026 | EXERCISE | $3.6M |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
27 filings · 3 bullish · 0 bearish · 24 neutral- NEUTRAL CLUSTERNov 10, 2026
Two Edwards Lifesciences insiders, including the CEO, executed open-market sales totaling $5.99M…
The sales are small relative to market cap and executed under 10b5-1 plans, so no bearish signal. Monitor for any unplanned insider selling in the coming weeks that would break the pattern.
- NEUTRAL CLUSTERNov 10, 2026
Three Edwards Lifesciences insiders, including the CEO and a CVP, sold a total of $6.05M in…
All sales were pre-arranged under 10b5-1 plans and are small relative to market cap, so they do not signal a change in outlook. The derivative exercises at $72.68 and immediate sales at ~$103…
- NEUTRAL 144Nov 10, 2026
Daniel J. Lippis, an officer of Edwards Lifesciences, filed a Form 144 notice of intent to sell…
The filing is a routine tax-related sale by an officer exercising stock options. The small size relative to market cap and the cashless exercise mechanism suggest no material insider sentiment…
- NEUTRAL CLUSTERNov 9, 2026
Two Edwards Lifesciences insiders, including the CEO, executed open-market sales totaling…
The sales are small relative to market cap and conducted under 10b5-1 plans, so they carry limited directional signal. The CEO's exercise-and-sell pattern is typical for option monetization. Monitor…
All EW filing & press-release reports (27)
- CLUSTER reportNov 10, 2026
- CLUSTER reportNov 10, 2026
- 144 reportNov 10, 2026
- CLUSTER reportNov 9, 2026
- 144 reportNov 9, 2026
- 144 reportNov 9, 2026
- 8-K reportNov 4, 2026
- INST-CLUSTER reportOct 29, 2026
- CLUSTER reportAug 31, 2026
- CLUSTER reportAug 28, 2026
- CLUSTER reportAug 26, 2026
- COURT-RULING reportAug 10, 2026
- CLUSTER reportJul 30, 2026
- CLUSTER reportJul 28, 2026
- CLUSTER reportMay 29, 2026
- CLUSTER reportMay 18, 2026
- CLUSTER reportMay 18, 2026
- CLUSTER reportMay 4, 2026
- CLUSTER reportMay 4, 2026
- CLUSTER reportMay 4, 2026
- 8-K reportMay 8, 2026
- 8-K reportMay 4, 2026
- 8-K reportApr 23, 2026
- CLUSTER reportApr 2, 2026
- DEFA14A reportMar 26, 2026
- DEFA14A reportMar 26, 2026
- INST-CLUSTER reportFeb 28, 2026